INmune Bio Reports Key Findings from Phase 2 MINDFuL Trial of XPro™ in Early Alzheimer’s Disease

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/21/2026

1. SPY
2. WBD
3. NVDA
4. PSKY
5. TSLA
6. AMD
7. USO
8. META
9. AMC
10. NUAI

Go back to INmune Bio Reports Key Findings from Phase 2 MINDFuL Trial of XPro™ in Early Alzheimer’s Disease
(NASDAQ: INMB) Delayed: 2.36 +0.03 (1.29%)
Previous Close $2.33    52 Week High $ 
Open $2.35    52 Week Low $ 
Day High $2.42    P/E N/A 
Day Low $2.29    EPS $ 
Volume 199,067       

(NASDAQ: INMB) Delayed: 2.36 +0.03 (1.29%)
Previous Close $2.33    52 Week High $ 
Open $2.35    52 Week Low $ 
Day High $2.42    P/E N/A 
Day Low $2.29    EPS $ 
Volume 199,067